980 related articles for article (PubMed ID: 25127013)
1. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
[TBL] [Abstract][Full Text] [Related]
2. Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term.
de Jong PG; Coppens M; Middeldorp S
Br J Haematol; 2012 Aug; 158(4):433-41. PubMed ID: 22734929
[TBL] [Abstract][Full Text] [Related]
3. [Optimal duration of anticoagulation of venous thromboembolism].
Savina EN; Couturaud F
J Mal Vasc; 2011 Dec; 36 Suppl 1():S28-32. PubMed ID: 22177766
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism.
Lecumberri R; Alfonso A; Jiménez D; Fernández Capitán C; Prandoni P; Wells PS; Vidal G; Barillari G; Monreal M;
Thromb Haemost; 2013 Oct; 110(4):834-43. PubMed ID: 23846721
[TBL] [Abstract][Full Text] [Related]
6. [Optimum duration of anticoagulant treatment after an episode of venous thromboembolism].
Couturaud F; Kearon C
Rev Pneumol Clin; 2008 Dec; 64(6):305-15. PubMed ID: 19084210
[TBL] [Abstract][Full Text] [Related]
7. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.
Kearon C; Spencer FA; O'Keeffe D; Parpia S; Schulman S; Baglin T; Stevens SM; Kaatz S; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Moll S; Connors JM; Ginsberg JS; Spadafora L; Julian JA;
Ann Intern Med; 2015 Jan; 162(1):27-34. PubMed ID: 25560712
[TBL] [Abstract][Full Text] [Related]
8. Duration of anticoagulation after venous thromboembolism in real world clinical practice.
Ageno W; Samperiz A; Caballero R; Dentali F; Di Micco P; Prandoni P; Becattini C; Uresandi F; Verhamme P; Monreal M;
Thromb Res; 2015 Apr; 135(4):666-72. PubMed ID: 25708926
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry.
Nieto JA; Camara T; Gonzalez-Higueras E; Ruiz-Gimenez N; Guijarro R; Marchena PJ; Monreal M;
Thromb Haemost; 2008 Nov; 100(5):789-96. PubMed ID: 18989522
[TBL] [Abstract][Full Text] [Related]
10. Bleeding complications during anticoagulant treatment in patients with cancer.
Kamphuisen PW; Beyer-Westendorf J
Thromb Res; 2014 May; 133 Suppl 2():S49-55. PubMed ID: 24862146
[TBL] [Abstract][Full Text] [Related]
11. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis.
Schulman S; Zondag M; Linkins L; Pasca S; Cheung YW; de Sancho M; Gallus A; Lecumberri R; Molnar S; Ageno W; Le Gal G; Falanga A; Hulegårdh E; Ranta S; Kamphuisen P; Debourdeau P; Rigamonti V; Ortel TL; Lee A
J Thromb Haemost; 2015 Jun; 13(6):1010-8. PubMed ID: 25851122
[TBL] [Abstract][Full Text] [Related]
12. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
Douketis J; Tosetto A; Marcucci M; Baglin T; Cushman M; Eichinger S; Palareti G; Poli D; Tait RC; Iorio A
Ann Intern Med; 2010 Oct; 153(8):523-31. PubMed ID: 20956709
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism in lymphoma: how effectively are we treating patients?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA
Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801
[TBL] [Abstract][Full Text] [Related]
14. Venous thromboembolism: risk factors for recurrence.
Zhu T; Martinez I; Emmerich J
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism.
Novacek G; Weltermann A; Sobala A; Tilg H; Petritsch W; Reinisch W; Mayer A; Haas T; Kaser A; Feichtenschlager T; Fuchssteiner H; Knoflach P; Vogelsang H; Miehsler W; Platzer R; Tillinger W; Jaritz B; Schmid A; Blaha B; Dejaco C; Eichinger S
Gastroenterology; 2010 Sep; 139(3):779-87, 787.e1. PubMed ID: 20546736
[TBL] [Abstract][Full Text] [Related]
16. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
[TBL] [Abstract][Full Text] [Related]
17. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study.
Riva N; Bellesini M; Di Minno MN; Mumoli N; Pomero F; Franchini M; Fantoni C; Lupoli R; Brondi B; Borretta V; Bonfanti C; Ageno W; Dentali F
Thromb Haemost; 2014 Sep; 112(3):511-21. PubMed ID: 24899092
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy.
Tzoran I; Brenner B; Sakharov G; Trujillo-Santos J; Lorenzo A; Madridano O; López-Sáez JB; Monreal M;
Eur J Intern Med; 2014 Nov; 25(9):821-5. PubMed ID: 25287697
[TBL] [Abstract][Full Text] [Related]
19. Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Noel-Savina E; Sanchez O; Descourt R; André M; Leroyer C; Meyer G; Couturaud F
Thromb Res; 2015 Jan; 135(1):78-83. PubMed ID: 25466839
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation after venous thromboembolism. Deciding on the optimal duration.
Eichinger S
Hamostaseologie; 2013 Aug; 33(3):211-7. PubMed ID: 23719863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
